Avrupa Birliği - Danca - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - parkinsons sygdom - anti-parkinson-lægemidler - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Avrupa Birliği - Danca - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Avrupa Birliği - Danca - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - bryst neoplasmer - endokrine terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Avrupa Birliği - Danca - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Avrupa Birliği - Danca - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Avrupa Birliği - Danca - EMA (European Medicines Agency)

orion corporation - toremifen - bryst neoplasmer - endokrine terapi - første linjehormonbehandling af hormonafhængig metastatisk brystkræft hos postmenopausale patienter. fareston anbefales ikke til patienter med østrogen-receptor negative tumorer.

Avrupa Birliği - Danca - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocytopenisk, idiopatisk - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Avrupa Birliği - Danca - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran natrium - amyloidose, familiær - andre narkotika stoffer - onpattro er indiceret til behandling af arvelige transthyretin-medieret amyloidose (hattr amyloidose) hos voksne patienter med fase 1 eller fase 2 polyneuropati.

Avrupa Birliği - Danca - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiske midler - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Avrupa Birliği - Danca - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulin glargin - diabetes mellitus - narkotika anvendt i diabetes - behandling af diabetes mellitus hos voksne, unge og børn i alderen 2 år og derover.